IRIS
LENCI, ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.802
AS - Asia 3.339
EU - Europa 1.402
Continente sconosciuto - Info sul continente non disponibili 415
SA - Sud America 383
AF - Africa 50
OC - Oceania 4
Totale 14.395
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.674
SG - Singapore 1.957
CN - Cina 450
RU - Federazione Russa 310
BR - Brasile 306
IT - Italia 293
VN - Vietnam 239
HK - Hong Kong 220
IE - Irlanda 154
DE - Germania 135
BD - Bangladesh 131
GB - Regno Unito 104
FR - Francia 87
JP - Giappone 78
KR - Corea 76
IN - India 71
FI - Finlandia 66
CA - Canada 60
SE - Svezia 46
PL - Polonia 42
MX - Messico 35
AR - Argentina 30
UA - Ucraina 28
ES - Italia 25
ID - Indonesia 22
NL - Olanda 22
AT - Austria 21
ZA - Sudafrica 14
BE - Belgio 13
CO - Colombia 11
CZ - Repubblica Ceca 11
TR - Turchia 11
CH - Svizzera 10
LT - Lituania 10
IQ - Iraq 9
IR - Iran 9
VE - Venezuela 9
EC - Ecuador 8
EG - Egitto 8
PK - Pakistan 8
HN - Honduras 7
JM - Giamaica 7
CL - Cile 6
MA - Marocco 6
PY - Paraguay 6
SA - Arabia Saudita 6
IL - Israele 5
KE - Kenya 5
TT - Trinidad e Tobago 5
AU - Australia 4
EU - Europa 4
PH - Filippine 4
QA - Qatar 4
TM - Turkmenistan 4
AL - Albania 3
AZ - Azerbaigian 3
BB - Barbados 3
BG - Bulgaria 3
CR - Costa Rica 3
DZ - Algeria 3
JO - Giordania 3
LK - Sri Lanka 3
MD - Moldavia 3
OM - Oman 3
PE - Perù 3
SN - Senegal 3
TN - Tunisia 3
TW - Taiwan 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AO - Angola 2
DK - Danimarca 2
KH - Cambogia 2
KZ - Kazakistan 2
MY - Malesia 2
NG - Nigeria 2
NO - Norvegia 2
PS - Palestinian Territory 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
TH - Thailandia 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AG - Antigua e Barbuda 1
BH - Bahrain 1
BJ - Benin 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
CV - Capo Verde 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GR - Grecia 1
GY - Guiana 1
KG - Kirghizistan 1
KN - Saint Kitts e Nevis 1
KW - Kuwait 1
LB - Libano 1
Totale 13.977
Salva come PNG Salva come JPEG
Città #
Wilmington 1.916
Houston 1.579
Singapore 723
Woodbridge 520
San Jose 444
Ashburn 408
New York 382
Fairfield 368
Chandler 315
Hong Kong 211
Council Bluffs 196
Beijing 181
Dublin 133
The Dalles 128
Los Angeles 126
Seattle 118
Cambridge 115
Medford 103
Santa Clara 102
Rome 100
Ann Arbor 91
Ho Chi Minh City 88
Elk Grove Village 86
Tokyo 75
Buffalo 53
Hanoi 52
Lauterbourg 49
Helsinki 48
Lawrence 47
Munich 47
Moscow 39
Dallas 34
São Paulo 33
Nuremberg 30
Orem 30
Warsaw 30
Chicago 29
San Diego 29
London 28
Menlo Park 26
North Bergen 24
Boardman 23
Montreal 23
Seoul 23
Atlanta 21
Brooklyn 21
Chennai 21
Dearborn 21
Mexico City 19
Frankfurt am Main 18
Palo Alto 18
Redondo Beach 17
Phoenix 16
Denver 15
Jacksonville 15
Milan 15
Washington 15
Creede 14
Engelhard 14
Jakarta 14
Shanghai 14
San Francisco 13
Brussels 12
Lappeenranta 12
Miami 12
Stockholm 12
Vienna 12
Poplar 10
Redwood City 10
Rio de Janeiro 10
Biên Hòa 9
Colorado Springs 9
Johannesburg 9
Manchester 9
Nanjing 9
Philadelphia 9
Toronto 9
Hangzhou 8
Hefei 8
Naples 8
Salt Lake City 8
Brno 7
Chandigarh 7
Columbus 7
Da Nang 7
Hải Dương 7
Suzhou 7
Charlotte 6
Haiphong 6
Hounslow 6
Madrid 6
Mumbai 6
Tampa 6
Amsterdam 5
Cagliari 5
Curitiba 5
Kingston 5
Las Vegas 5
Minneapolis 5
Nairobi 5
Totale 9.804
Salva come PNG Salva come JPEG
Nome #
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 532
Pitfalls in the reporting of upper endoscopy features in cirrhotic patients 453
Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation 450
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 420
Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients 378
An unusual duodenal polyp causing anemia in a liver-transplanted patient 351
Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study 346
Tips for TIPS: A combined percutaneous and transjugular approach for intrahepatic portosystemic shunt placement after liver transplant 346
Clinical Operational Tolerance and Immunosuppression Minimization in Kidney Transplantation: Where Do We Stand? 345
HDV can constrain HBV genetic evolution in hbsag: Implications for the identification of innovative pharmacological targets 337
Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger? 336
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 313
Impact of new DAA therapy on real clinical practice: A multicenter region-wide cohort study 309
Trans-splenic Embolization Plus Partial Splenic Embolization for Management of Variceal Bleeding Due to Left-Sided Portal Hypertension 306
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 304
Pro-inflammatory signalling and gut-liver axis in non-alcoholic and alcoholic steatohepatitis: differences and similarities along the path 302
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 293
Renal Function, Adherence and Quality of Life Improvement After Conversion From Immediate to Prolonged-Release Tacrolimus in Liver Transplantation: Prospective Ten-Year Follow-Up Study 283
HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma 264
Liver Transplantation For HDV/HBV Coinfection In Italy: An Intention-To-Treat Analysis Of Long-Term Outcomes 254
Dual role of bile acids on the biliary epithelium: Friend or foe? 253
Platelets and hepatocellular cancer: Bridging the bench to the clinics 233
Evaluation of liver fibrosis in cirrhotic patients: comparison between elastosonography and fibroscan 222
Domino liver transplantation: Where are we now? 215
Liver transplantation for hepatocellular carcinoma: Where do we stand? 211
De novo malignancies after liver transplantation: The effect of immunosuppression-personal data and review of literature 209
Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: A real-life strategy 206
Vascular anomalies of the celiac trunk and implications in treatment of HCC with TACE. Description of a case and review of the literature 204
Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study 162
Cholangiocarcinoma: Bridging the translational gap from preclinical to clinical development and implications for future therapy 153
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 144
Transarterial chemoembolization for hepatocellular carcinoma in Fontan surgery patient 142
Fairness and pitfalls of the Italian waiting list for elective liver transplantation: The ECALITA registry study 140
Moving forward in the treatment of cholangiocarcinoma 132
Serum Levels of Granulocyte-Macrophage-colony-stimulating Factor and Stem-cell Factor During Liver Regeneration after Partial Hepatectomy in Humans 121
Current strategies to minimize ischemia-reperfusion injury in liver transplantation: a systematic review 117
Natremia and liver transplantation: The right amount of salt for a good recipe 112
Chronic rejection after liver transplantation: Opening the Pandora's box 112
Molecular mechanisms linking risk factors to cholangiocarcinoma development 110
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 110
Functional Role of the Secretin/Secretin Receptor Signaling During Cholestatic Liver Injury 104
Prevalence of hepatitis D virus infection in Central Italy has remained stable across the last 2 decades with dominance of subgenotypes 1 and characterized by elevated viral replication 103
Cyclic AMP Signaling in Biliary Proliferation: A Possible Target for Cholangiocarcinoma Treatment? 103
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C 103
The acquisition of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer in vivo, impairs HBsAg secretion and affects its structural stability in vitro 102
Sequence of events leading to primary biliary cholangitis 102
Gastrointestinal endoscopy in cirrhotic patient: Issues on the table 100
COVID-19 in normal, diseased and transplanted liver 100
Electronic Outpatient Referral System for Liver Transplant Improves Appropriateness and Allows First Visit Triage 99
The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma 99
Liver transplantation performed in a SARS-CoV-2 positive hospitalized recipient using a SARS-CoV-2 infected donor 98
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study 97
HDV epidemic in Central Italy is stable over the last two decades and is characterized by the circulation of multiple HDV subgenotypes 1 inducing different inflammatory stimuli 94
Successful clinical and virological outcomes of liver transplantation for HDV/HBV-related disease after long-term discontinuation of hepatitis B immunoglobulins 94
HDV replicative activity parallels the production of the three HBsAg forms (Large, Middle and Small HBsAg) and its pathogenetic impact is exacerbated by concomitant HBV replication 93
Superiority of the new sex-adjusted models to remove the female disadvantage restoring equity in liver transplant allocation 92
Correction to: Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group (Hepatology International, (2020), 14, 6, (930-943), 10.1007/s12072-020-10091-5) 92
Towards tolerance in liver transplantation 89
The acquisition of positively charged amino acids in HBsAg C- terminus impairs HBsAg secretion, affects its structural stability and is associated with HBV-induced liver cancer 88
Secondary bile acids and the biliary epithelia: The good and the bad 86
New strategies on management of hepatitis B virus after liver transplantation: complete and sustained weaning of HBV prophylaxis in a selected cohort of patients transplanted due to HBV-related cirrhosis 85
Stable temporal trend of HDV seroprevalence in central Italy across the last two decades with the circulation of HDV sub-genotypes 1 inducing different inflammatory stimuli 84
Higher levels of three HBsAg forms (Large, Middle and Small HBsAg) are associated with HDV replication and with the degree of disease and liver damage. 84
A peculiar HBsAg isoforms composition characterizes chronic HDV coinfection respect to HBV mono-infection, with higher middle-/large-HBs levels paralleling HDV activity. 83
The Effects of Sustained Immunosuppression Withdrawal After Liver Transplantation on Metabolic Syndrome 83
HDV INFECTION IS STABLE IN CENTRAL ITALY ACROSS THE LAST TWO DECADES AND IS CHARACTERIZED BY THE CIRCULATION OF MULTIPLE HDV SUB-GENOTYPES 1 WITH A DIFFERENT PRO-INFLAMMATORY POTENTIAL 82
Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance 82
Sarco-Model: a score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation 79
Role of Cone-Beam CT in the Intraprocedural Evaluation of Chemoembolization of Hepatocellular Carcinoma 79
The Italian data on SARS-CoV-2 infection in transplanted patients support an organ specific immune response in liver recipients 78
Chronic HDV coinfection (CHD) is characterized by a different HBsAg isoforms composition respect to HBV mono-infection with higher middle- and large-HBs levels paralleling the replicative and cytolytic activity of HDV. 78
Chronic HDV coinfection (CHD) is characterized by a more elevated production of Middle and Large HBsAg than HBV mono-infection, that parallels HDV replicative and cytolytic activity. 78
The Many Faces of Metabolic Dysfunction-Associated Fatty Liver Disease Treatment: From the Mediterranean Diet to Fecal Microbiota Transplantation 77
Development of Autoimmune Hepatitis after COVID-19 Infection in Vaccinated Women 76
THE ENRICHMENT OF POSITIVELY CHARGED AMINO ACIDS IN HBsAg C-TERMINUS IMPAIRS HBsAg SECRETION, AFFECTS ITS STRUCTURAL STABILITY AND IS CORRELATED WITH HBV-INDUCED LIVER CANCER. 75
PATHWAYS UNDERLYING HDV PERSISTENCE ACT INDEPENDENTLY FROM THE EXTENT OF HBV RESEVOIR AND ARE SUSTAINED BY AN ABUNDANT PRODUCTION OF HBSAG DERIVED FROM INTEGRATED HBV-DNA P 214 73
Benign disease and unexpected histologocal findings after pancreaticoduodenectomy: The role of endoscopic ultrasound fine needle aspiration 72
The intrahepatic activity of Hepatitis Delta virus is sustained by an abundant production of HBs transcripts, mainly derived from integrated HBV-DNA, and is not strictly related to the extent of HBV reservoir 71
Repeated TACE in HCC after Fontan surgery and situs viscerum inversus: A case report 70
Chronic HDV infection is sustained by an intense HBsAg production fromintegrated HBVDNA in the setting of a limited or even absent HBV reservoir. 67
Reduction in bile leaks following adult split liver transplant using a fibrin-collagen sponge: A pilot study 67
Chronic HDV coinfection is characterized by a peculiar HBsAg isoforms composition respect to HBV mono-infection, with higher middle-/large-HBs levels paralleling HDV activity. 65
HBsAg production from integrated HBV-DNA sustains HDV persistence in the setting of a limited or even absent HBV reservoir 62
HDV persistence is sustained by HBsAg mainly derived from integrated HBV-DNA and is independent from the extent of HBV reservoir 61
Pathways sustaining HDV activity act independently from the size of HBV resevoir and are fueled by an abundant expression of HBsAg from integrated HBV-DNA 58
Use of intravascular ultrasound to improve diagnosis and treatment of transjugular intrahepatic portosystemic shunt dysfunction in patients in the long-term follow-up 54
Saline Contrast Echocardiography in Patients With Hepatopulmonary Syndrome Awaiting Liver Transplantation 47
null 42
A high degree of genetic variability characterises HDV sub-genotypes 1 and can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity. 37
HDV persistence acts independently from HBV reservoir extent and is sustained by HBsAg production mainly derived from integrated HBV-DNA 34
HBV integration can sustain intrahepatic HDV activity and can modulate HBV pathogenetic potential. 29
HDV sub-genotype 1 is characterized by increased genetic variability, which can promote the emergence of divergent genetic pathways that modulate HDV replicative potential and cytolytic activity. 28
An increased genetic variability characterises HDV sub-genotypes 1 and can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity 27
HDV sub-genotype 1 is characterized by increased genetic variability, which can promote the emergence of divergent genetic pathways that modulate HDV replicative potential and cytolytic activity. 23
Intra-hepatic HDV replicative activity can be sustained by HBsAg production from HBV-DNA integration and can modulate virological response to bulevirtide 22
Chronic HDV Infection Shows Higher HBsAg Isoform Levels than HBV Infection, Paralleling HDV Replicative Activity 15
Totale 14.395
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.402
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.402
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022504 0 0 18 27 9 72 46 24 65 56 38 149
2022/2023796 74 77 46 88 78 152 72 72 73 11 32 21
2023/2024478 60 16 43 13 62 135 9 14 14 54 3 55
2024/20252.563 55 347 205 105 27 183 164 59 167 173 619 459
2025/20264.318 415 146 412 419 360 335 506 476 535 364 207 143
2026/2027594 232 203 159 0 0 0 0 0 0 0 0 0
Totale 14.395